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Abstract
Patients with gastric cancer have a variety of immunological abnor-
malities. In the present study the lymphocytes and their subsets were
determined in the peripheral blood of patients with gastric cancer (N =
41) both before and after surgical treatment. The percent of helper/
inducer CD4 T cells (43.6 ± 8.9) was not different after tumor
resection (43.6 ± 8.2). The percent of the cytotoxic CD8+ T cell
population decreased significantly, whether patients were treated
surgically (27.2 ± 5.8%, N = 20) or not (27.3 ± 7.3%, N = 20)
compared to individuals with inflammatory disease (30.9 ± 7.5%) or
to healthy individuals (33.2 ± 7.6%). The CD4/CD8 ratio conse-
quently increased in the group of cancer patients. The peripheral blood
lymphocytes of gastric cancer patients showed reduced responsive-
ness to mitogens. The defective blastogenic response of the lympho-
cytes was not associated with the production of transforming growth
factor beta (TGF-ß) since the patients with cancer had reduced produc-
tion of TGF-ß1 (269 ± 239 pg/ml, N = 20) in comparison to the normal
individuals (884 ± 175 pg/ml, N = 20). These results indicate that the
immune response of gastric cancer patients was not significantly
modified by surgical treatment when evaluated four weeks after
surgery and that the immunosuppression observed was not due to an
increase in TGF-ß1 production by peripheral leukocytes.
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Introduction
The incidence of gastric cancer has been
increasing in many countries, except in Ja-
pan and a few other countries where the
health care system has implemented effec-
tive strategies for the early diagnosis of the
disease (1). Many gastric cancer patients
have a variable degree of immunological
impairment, including decreased cellular im-
munity (2,3). Immunity to cancer is known to
be affected by the function of the lympho-
cyte subsets, consisting of helper/inducer
CD4 T cells and cytotoxic/suppressor CD8+
T cells. Patients with malignant disease pres-
ent poor in vitro lymphocyte transformation
that is usually associated with a poorer prog-
nosis of the disease (4). The reduction in
proliferative response is associated with the
increase of cytokines with immunosuppres-
sive effects such as transforming growth fac-
tor beta (TGF-ß).
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TGF-ß are multifunctional polypeptides
that influence the growth and differentiation
of cells, as well as their adhesion, migration,
angiogenesis, extracellular matrix formation
and immune functions (5). These polypep-
tides can have either positive or negative ef-
fects on in vitro cell proliferation depending
on cell type, epithelial origin and immune
systems. TGF-ß is an immunosuppressive cy-
tokine which inhibits T and B cell prolifera-
tion (6), natural killer cell cytotoxic activity,
and the generation of T cell cytotoxicity (7,8).
Elevated levels of TGF-ß1 have been reported
in breast (9), brain (10) and pancreatic (11)
cancers and this overexpression due to its
immunosuppressive effect has been associ-
ated with the progression of the disease.
The present study was conducted to ex-
amine the quantitative changes in the subsets
of lymphocytes and the level of TGF-ß in the
proliferative response of gastric cancer pa-
tients on two occasions, i.e., before and after
surgical treatment.
Material and Methods
Subjects
Forty-one patients with advanced stom-
ach cancer (27 males and 14 females, me-
dian age 60.6 years, range 37-76 years) and
20 controls (with duodenal ulcers or reflux
gastritis, 12 males and 8 females, median age
50.7, range 21-70 years) were studied. All
patients were hospitalized in the Department
of Surgery, Campinas University Hospital,
Campinas, SP, Brazil, during the period from
March to November, 1998. Twenty patients
underwent extended radical gastrectomy and
lymphadenectomy D2, and 21 patients,
whose condition prevented resection, re-
ceived palliative treatment. Criteria for in-
clusion in the study were histologically
proven adenocarcinoma of the stomach, no
previous therapy, no liver metastasis, perito-
neal carcinomatosis or ascites. Cancer stag-
ing was determined according to the TNM
staging groups approved by the International
Union Against Cancer (12). The study was
approved by the Ethics Committee of Uni-
versidade Estadual de Campinas, UNICAMP,
and the volunteers gave written informed
consent to participate in the study.
Measurement of the quantity of lymphocytes
and their subsets
Three milliliters of peripheral venous blood
was collected into EDTA tubes and analyzed
with a CELL DYN 1700 counter. The white
blood cells in the sample were counted imme-
diately using an automatic blood cell counter
and the result is reported both as a percent and
an absolute number. Lymphocytes and their
subsets were identified with a FACScan (BD
Biosciences, San Diego, CA, USA) using fluo-
rescent monoclonal antibodies and flow cy-
tometry. Monoclonal antibodies, anti-CD3,
T cell, anti-CD4, helper/inducer and anti-CD8,
suppressor/cytotoxic cells were used. Before
counting, the lymphocytes were gated among
the white blood cells, with lymphocyte size
being used to distinguish them from neutro-
phils and monocytes.
Mitogen-induced blastogenesis
Peripheral blood lymphocytes were iso-
lated from heparinized blood by centrifuga-
tion on a Ficoll-Hypaque density gradient.
The cells were suspended (2 x 105 cells/well)
in RPMI 1640 (Sigma, St. Louis, MO, USA)
containing 10% AB human serum, 0.125%
gentamicin and 1% glutamine. Cell suspen-
sions (200 µl) supplemented with concanava-
lin A (10 µg/ml) were cultured in 96-well
microplates at 37ºC in a humidified atmos-
phere of 5% CO2 in air. After 72 h of culture,
1 µCi [3H]-thymidine (New England Nuclear,
Boston, MA, USA) was added to each well.
After an additional 12-h incubation, [3H]-
thymidine uptake was determined using a
liquid scintillation spectrometer (Beckman
Coulter Inc., San Jose, CA, USA).
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Capture ELISA for cytokine quantification (13)
TGF-ß antibody (polyclonal antibody ob-
tained from R&D Systems, Minneapolis, MN,
USA; 1 µg/ml in PBS, pH 7.4) was added to
96-well microtiter plates (Immulon I, Nunc,
Roskilde, Denmark). After overnight incu-
bation at 4ºC, the plates were washed three
times with ELISA washing buffer (PBS con-
taining 0.05% Tween 20 and 0.001% Thime-
rosal) and blocked for l h with ELISA diluent
(PPB containing 0.05% Tween 20 and l%
BSA). The plates were washed three times
with washing buffer and 100 µl of standard,
control, or sample blood was added to dupli-
cate wells for overnight incubation at 4ºC.
The plates were again washed three times
with washing buffer and incubated for l h at
room temperature with 1 µg/ml TGF-ß mono-
clonal antibody (Genzyme Diagnostics, Cam-
bridge, MA, USA) in ELISA buffer. The
plates were then washed three times with
ELISA washing buffer and incubated for an
additional hour with 1:2000 biotinylated anti-
mouse IgG (Vector, Burlingame, CA, USA).
The avidin-peroxidase complex and the sub-
strate were then added. Orthophenylene di-
amine (Sigma) prepared at 0.5 mg/ml in 50
mM hydrogen peroxide was added and left
to stand 30 min at room temperature and the
plates were read at 492 nm.
Statistical analysis
The statistical significance of the results
was determined by the Student t-test and the
Friedman and Kruskal-Wallis test. A P value
smaller than 0.05 was considered to be sig-
nificant.
Results
Lymphocytes and their subsets
Lymphocyte subsets were quantified in
normal control individuals, in patients with
gastric cancer both before and after surgical
treatment, and in patients with inflammatory
non-neoplastic disease. Single fluorescence
analysis was performed with a flow cytom-
eter after gating the lymphocyte populations.
The results for the T cell subpopulations are
reported as percent of lymphocytes.
There was no significant difference in
white blood cell count between the controls
and the patients with advanced gastric can-
cer prior to surgery. However, after surgery,
the number of white blood cells increased.
No significant changes were observed in
the number of CD4+ T lymphocytes, al-
though CD8+ T cells (in absolute number
and in percent) were decreased after surgery
(P<0.05; Table 1).
Mitogen-induced blastogenesis
Changes in the proliferative response of
lymphocytes were used to evaluate cellular
immune responses, as shown in Figure 1.
Concanavalin A-induced blastogenesis sig-
nificantly decreased in gastric cancer pa-
tients before surgery and in the non-resect-
able group compared to normal controls (non-
resectable, 5830 ± 6320 cpm; preoperative,
9176 ± 4342 cpm vs normal, 45,000 ± 8000
cpm; P<0.001). However, four weeks after
surgical treatment, no statistically signifi-
cant differences were demonstrable (preop-
Table 1. Subsets of T lymphocytes in peripheral blood cells of patients with gastric
cancer before and after surgical treatment and in patients with inflammatory disease.
Normal Preoperative Postoperative Inflammatory
individuals patients patients disease group
(N = 20) (N = 20) (N = 20) (N = 21)
Leukocytes (103) 6.7 ± 1.9 6.03 ± 1.7 6.5 ± 2.1 6.8 ± 3.1
%Lymphocytes 34.3 ± 8.3 29.9 ± 5.46 30.5 ± 9.23 29.0 ± 11.8
%CD3 27.8 ± 7.9 25.3 ± 8.9 24.8 ± 8.5 27.9 ± 12.0
%CD4 41.6 ± 8.2 43.6 ± 8.9 43.1 ± 8.2 39.5 ± 10.3
%CD8 33.2 ± 7.6 27.2 ± 5.8* 27.3 ± 7.3* 30.9 ± 7.5
CD4/CD8 1.28 ± 0.54 1.69 ± 0.63 1.75 ± 0.76 1.52 ± 0.91
The T cell subpopulations were quantified before surgery and 20 days after treatment
using monoclonal antibodies and flow cytometry.
*P<0.05 compared to normal individuals and the inflammatory disease group (Student
t-test).
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erative, 9176 ± 4342 cpm vs postoperative,
6870 ± 2020 cpm).
Production of TGF-ß by mononuclear cells
Concanavalin A stimulation of cells for
72 h was followed by TGF-ß quantification.
The mean TGF-ß production by mononuclear
cells from patients was 269 ± 239 pg/ml
before surgical treatment vs 265 ± 151 pg/ml
after surgical treatment; patients with non-
resectable tumors produced 354 ± 142 pg/
ml. The differences were not statistically
significant. Peripheral blood cells from pa-
tients with inflammatory disease produced
921 ± 229 vs 884 ± 175 pg/ml for normal
individuals, again no significant difference
was demonstrable between groups. How-
ever, there was a significant decrease in
TGF-ß production by the group of patients
with gastric cancer both before and after
surgical treatment (P<0.01; Figure 2).
Effect of TGF-ß on the proliferative response
To determine if the suppression of the
proliferative response was due to the pro-
duction of TGF-ß, a neutralizing TGF-ß an-
tibody was added to the culture (25 µg/ml),
and the proliferative response was evalu-
ated. The presence of an anti-TGF-ß mono-
clonal antibody in the culture did not restore
the proliferative response to concanavalin A
of patients with gastric cancer (Figure 3),
indicating that TGF-ß was not involved in
the suppression of the proliferative response.
Discussion
We studied the immune response of pa-
tients with gastric cancer both before and
after surgery; the subpopulation of T lym-
phocytes was quantified, and the prolifera-
tive response of the lymphocytes, as well as
the levels of TGF-ß were investigated.
The percent of suppressor/cytotoxic T
cells (CD8) was significantly lower for both
Figure 1. Proliferative response of lymphocytes from gastric cancer
patients and normal controls. Peripheral blood lymphocytes were cul-
tured for 48 h after stimulation with concanavalin A (10 µg/ml). Blast
transformation was evaluated by [3H]-thymidine incorporation. *P<0.05
compared to normal individuals (Kruskal-Wallis test).
Figure 2. Transforming growth factor (TGF-ß) production by peripheral
blood leukocytes from gastric cancer patients before and after surgical
treatment, normal individuals, and patients with non-neoplastic dis-
ease, previously stimulated with concanavalin A (10 µg/ml) and quanti-
fied in the supernatant by ELISA. *P<0.05 compared to normal indi-
viduals and the inflammatory disease group (Student t-test) and P>0.05
comparing preoperative cancer patients to postoperative cancer pa-
tients (Friedman test).
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preoperative and postoperative patients,
whereas the percent of helper/inducer (CD4)
cells was comparable to that of the normal
control and inflammatory disease groups.
Thus, the CD4/CD8 ratio increased in pa-
tients with gastric cancer. Note that the in-
crease in the CD4/CD8 ratio contradicts data
obtained in a previous study (3). Various
investigators have not detected significant
modifications of CD8+ lymphocyte popula-
tions in gastric cancer patients. The present
data show a reduction in this cell population,
which indicates an important deficiency in
cell immunity since the CD8+ T cell popula-
tion is directly involved in combating cancer
cells. It has been reported that major histo-
compatibility complex class I-restricted
CD8+ T cells from gastric cancer patients
react specifically with autologous tumor cells
(14-16). Moreover, adoptively transferred,
tumor-specific CD8+ T cells induce the re-
gression of micrometastases (17). Therefore,
the reduction in the number of CD8+ T cells
in the peripheral blood of cancer patients
indicates a severe deficiency in the defense
of the organism against the growth of tumor
cells.
In addition to the quantitative changes in
the number of T lymphocyte subsets, the
functional state of these cells was investi-
gated. As previously reported, patients with
gastric cancer had a significant decrease in
lymphocyte proliferative response (4), and
we demonstrated that this response did not
improve significantly after surgery. Immu-
nosuppressive cytokines produced by leuko-
cytes such as TGF-ß are associated with the
inhibition of the proliferative response of
lymphocytes. TGF-ß overexpression has also
been associated with the progression of the
various types of cancer, as well as with the
decreased survival of cancer patients. This
suggests that the characteristics of TGF-ß
allow these polypeptides to enhance cancer
cell growth. Prostatic cancer accompanied
by the overproduction of TGF-ß1 exhibits
faster growth and more extensive metastases
than identical tumor cells without TGF-ß1
expression.
In the present study, when the level of
TGF-ß produced by peripheral blood leuko-
cytes from cancer patients was quantified, it
was possible to observe that cytokines were
present at much lower levels in comparison
with the control group. Although monocytes
have been considered to be the principal
source of TGF-ß in human peripheral blood
(18), stimulated lymphocytes are also an
important source of TGF-ß (6). Interestingly,
TGF-ß has been reported to promote the
growth of CD8+ T cells (19-22); this obser-
vation may explain the reduction of the CD8+
T cell population in gastric cancer patients.
To emphasize that the decrease in the prolif-
erative response of the lymphocytes was not
exclusively due to the increase in TGF-ß
production, we also demonstrated that exog-
enous addition of anti-TGF-ß monoclonal
antibodies slightly increases the prolifera-
tive response of lymphocytes, although it
does not block the observed suppression.
Normal group +
Con A +
anti-TGF-ß
Normal group
+ Con A
Cancer
patients +
Con A +
anti-TGF-ß
Cancer
patients +
Con A
*
Figure 3. Proliferative response of peripheral blood lymphocytes from
gastric cancer patients stimulated with concanavalin A (Con A) in the
presence and absence of anti-TGF-ß antibody. *P<0.05 comparing nor-
mal group + Con A + anti-TGF-ß to cancer patients + Con A + anti-TGF-ß
and normal group + Con A to cancer patients + Con A (Student t-test).
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Although some investigators have shown
elevated serum levels of TGF-ß in gastric
cancer patients (22,23), our data are in agree-
ment with others who suggested that the
effect of TGF-ß in gastric cancer is concen-
trated at the site of tumor growth, and pro-
duction of TGF-ß in the tumor does not
contribute to the total amount of TGF-ß in
the blood circulation (24). It is known that
gastric tumor cells synthesize a large amount
of TGF-ß (25-29) which may inhibit the
local immune response, especially that of
intratumoral lymphocytes. Inasmuch as gas-
tric cancer cells are often resistant to TGF-ß-
mediated growth inhibition (30), the local
overexpression of TGF-ß may also act via
these mechanisms to enhance the growth
and metastasis of this cancer in vivo.
Surgical resection is the treatment of
choice in gastric cancer, although the major-
ity of patients with advanced gastric cancer
have a poor prognosis even after curative
resection. These data show that the surgical
removal of a tumor is insufficient to over-
come the profound immunological depres-
sion found in patients with gastric cancer.
Therefore, other treatment modalities mainly
involving the modulation of the immune
response must be associated with the surgi-
cal treatment against the growth of neoplas-
tic cells.
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